• Je něco špatně v tomto záznamu ?

Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson's Disease

P. Havránková, J. Roth, V. Čapek, J. Klempíř, M. Baláž, I. Rektorová, V. Haň, M. Skorvanek, K. Gmitterová, M. Minár, P. Valkovič, M. Kaiserová, P. Kaňovský, M. Grofik, E. Kurča, J. Necpál, R. Jech

. 2024 ; 58 (6) : 586-592. [pub] 20241120

Jazyk angličtina Země Polsko

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25004186

AIM OF STUDY: To determine whether a high dose of levodopa-carbidopa intestinal gel (LCIG), expressed as levodopa equivalent daily dose (LE daily dose), is a risk factor for acute polyneuropathy in patients treated with LCIG. CLINICAL RATIONALE FOR STUDY: Treatment with LCIG is an effective device-assisted therapy in the advanced stages of Parkinson's Disease (PD). Polyneuropathy is a well-known complication of PD treatment. Patients treated with oral levodopa usually suffer from sub-clinical or mild chronic sensory polyneuropathy. However, severe acute polyneuropathy occurs in patients treated with LCIG, which is causally related to the treatment and leads to its immediate discontinuation. The etiology is not yet clear, but some patients with acute polyneuropathy have been given high doses of LCIG. MATERIAL AND METHODS: A retrospective multicentre study of patients treated with LCIG was performed. Patients with acute polyneuropathy were subjected to a detailed analysis including statistical processing. RESULTS: Of 183 patients treated with LCIG in seven centres, six patients (five females, median age 63 years) developed acute polyneuropathy with LCIG discontinuation. The median (interquartile range) initial and final LE daily dose in patients with and without acute polyneuropathy was 3,015 (2,695-3,184) and 1,898 (1,484-2,167) mg, respectively. The final LE daily dose of 2,605 mg cut-off had 83% sensitivity and 93% specificity for the prediction of acute polyneuropathy. CONCLUSIONS AND CLINICAL IMPLICATIONS: The risk of acute polyneuropathy in LCIG-treated patients was associated with a daily LE dose of greater than 2,605 mg or with more than a 62% increase in the daily LE dose during LCIG treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25004186
003      
CZ-PrNML
005      
20250206110004.0
007      
ta
008      
250121s2024 pl f 000 0|eng||
009      
AR
024    7_
$a 10.5603/pjnns.100132 $2 doi
035    __
$a (PubMed)39564873
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Havránková, Petra $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic. petra.havrankova@vfn.cz $1 https://orcid.org/0000000277315129
245    10
$a Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson's Disease / $c P. Havránková, J. Roth, V. Čapek, J. Klempíř, M. Baláž, I. Rektorová, V. Haň, M. Skorvanek, K. Gmitterová, M. Minár, P. Valkovič, M. Kaiserová, P. Kaňovský, M. Grofik, E. Kurča, J. Necpál, R. Jech
520    9_
$a AIM OF STUDY: To determine whether a high dose of levodopa-carbidopa intestinal gel (LCIG), expressed as levodopa equivalent daily dose (LE daily dose), is a risk factor for acute polyneuropathy in patients treated with LCIG. CLINICAL RATIONALE FOR STUDY: Treatment with LCIG is an effective device-assisted therapy in the advanced stages of Parkinson's Disease (PD). Polyneuropathy is a well-known complication of PD treatment. Patients treated with oral levodopa usually suffer from sub-clinical or mild chronic sensory polyneuropathy. However, severe acute polyneuropathy occurs in patients treated with LCIG, which is causally related to the treatment and leads to its immediate discontinuation. The etiology is not yet clear, but some patients with acute polyneuropathy have been given high doses of LCIG. MATERIAL AND METHODS: A retrospective multicentre study of patients treated with LCIG was performed. Patients with acute polyneuropathy were subjected to a detailed analysis including statistical processing. RESULTS: Of 183 patients treated with LCIG in seven centres, six patients (five females, median age 63 years) developed acute polyneuropathy with LCIG discontinuation. The median (interquartile range) initial and final LE daily dose in patients with and without acute polyneuropathy was 3,015 (2,695-3,184) and 1,898 (1,484-2,167) mg, respectively. The final LE daily dose of 2,605 mg cut-off had 83% sensitivity and 93% specificity for the prediction of acute polyneuropathy. CONCLUSIONS AND CLINICAL IMPLICATIONS: The risk of acute polyneuropathy in LCIG-treated patients was associated with a daily LE dose of greater than 2,605 mg or with more than a 62% increase in the daily LE dose during LCIG treatment.
650    _2
$a lidé $7 D006801
650    12
$a levodopa $x aplikace a dávkování $x škodlivé účinky $7 D007980
650    12
$a karbidopa $x aplikace a dávkování $x škodlivé účinky $7 D002230
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a Parkinsonova nemoc $x farmakoterapie $7 D010300
650    _2
$a lidé středního věku $7 D008875
650    12
$a fixní kombinace léků $7 D004338
650    _2
$a senioři $7 D000368
650    12
$a polyneuropatie $x chemicky indukované $x farmakoterapie $7 D011115
650    12
$a gely $7 D005782
650    _2
$a retrospektivní studie $7 D012189
650    12
$a antiparkinsonika $x škodlivé účinky $x aplikace a dávkování $7 D000978
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Roth, Jan $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
700    1_
$a Čapek, Václav $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
700    1_
$a Klempíř, Jiří $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
700    1_
$a Baláž, Marek $u First Department of Neurology, Medical Faculty, St. Anne's Teaching Hospital, Masaryk University, Brno, Czech Republic
700    1_
$a Rektorová, Irena $u First Department of Neurology, Medical Faculty, St. Anne's Teaching Hospital, Masaryk University, Brno, Czech Republic
700    1_
$a Haň, Vladimír $u Department of Neurology, Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovakia $u Department of Neurology, University Hospital of Louis Pasteur, Kosice, Slovakia
700    1_
$a Skorvanek, Matej $u Department of Neurology, Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovakia $u Department of Neurology, University Hospital of Louis Pasteur, Kosice, Slovakia
700    1_
$a Gmitterová, Karin $u Second Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Minár, Michal $u Second Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Valkovič, Peter $u Second Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Kaiserová, Michaela $u Department of Neurology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Kaňovský, Petr $u Department of Neurology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Grofik, Milan $u Department of Neurology Comenius University's Jessenius Faculty of Medicine and University Hospital, Martin, Slovakia
700    1_
$a Kurča, Egon $u Department of Neurology Comenius University's Jessenius Faculty of Medicine and University Hospital, Martin, Slovakia
700    1_
$a Necpál, Ján $u Second Department of Neurology, Faculty of Medicine, Comenius University in Bratislava, Slovakia $u Department of Neurology, Zvolen Hospital, Zvolen, Slovakia
700    1_
$a Jech, Robert $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
773    0_
$w MED00003489 $t Neurologia i neurochirurgia polska $x 0028-3843 $g Roč. 58, č. 6 (2024), s. 586-592
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39564873 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206105959 $b ABA008
999    __
$a ok $b bmc $g 2263740 $s 1240193
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 58 $c 6 $d 586-592 $e 20241120 $i 0028-3843 $m Neurologia i neurochirurgia polska $n Neurol Neurochir Pol $x MED00003489
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace